Clover Biopharmaceuticals, Ltd. (HKG:2197)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.140
+0.240 (12.63%)
At close: Mar 10, 2026
548.48%
Market Cap 2.47B
Revenue (ttm) 56.73M
Net Income (ttm) -996.69M
Shares Out 1.30B
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,839,500
Average Volume 3,431,079
Open 1.890
Previous Close 1.900
Day's Range 1.890 - 2.210
52-Week Range 0.185 - 3.180
Beta 3.42
RSI 51.77
Earnings Date Mar 27, 2026

About Clover Biopharmaceuticals

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 243
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2197
Full Company Profile

Financial Performance

In 2024, Clover Biopharmaceuticals's revenue was 38.42 million, a decrease of -2.13% compared to the previous year's 39.26 million. Losses were -903.43 million, 552.1% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.